Will the new Alzheimer’s drug put pressure on Medicare premiums?

The FDA approved the drug Leqembi, and Medicare will cover the new expensive new drug that promises the slowing the advance of Alzheimer’s disease. Although the last Alzheimer’s disease drug caused Medicare Part B premiums to rise an incredible 14.5 percent, it will be different this time. However, the expected cost of $26,500 per year per patient; will put new pressure on Medicare premiums. Mark Miller explains how Leqembi will add cost pressures for Medicare. Read Mr. Miller’s article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org